Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of SL- …